Plasma Level of Various Omega-3 Lipids

This is a single center, open design, randomized, controlled, cross-over trial with 3 test periods and 3 products (one test period per product). The three different test periods will be separated by a washout period of at least 6 days (up to 21 days).

Inclusion criteria

• Aged between 18 and 65 years old
• BMI in the normal and overweight range (18.5 to 29.9 kg/m2)
• Able to understand and to sign written informed consent prior to trial entry
• Informed consent signed

Exclusion criteria

• Food allergy
• Documented clinically relevant disease impacting the endpoints of the study or the safety of the subject, as determined by the medical (screening) visit:

i. Malabsorptive disorders including but not limited to pancreatitis, Crohn's disease, etc. ii. Known hypertriglyceridemia (on anamnesis) iii. Known Type2 Diabetes Mellitus

• Under medication that may impact:

• Dietary fat absorption and metabolism like statins, bile acid sequestrants, lipid lowering medications, or fibrates (to the opinion of the investigator)
• Coagulation (blood thinning medications, anticoagulants). Indeed, OM3 have been shown to possibly exert some bleeding by themselves that may increase the bleeding effects of aspirin and anticoagulants
• Having taken omega-3, EPA/DHA, fish oil supplementation for more than two consecutive weeks during the last 2 months
• Having given blood within the last month, or willing to make a blood donation until one month following the end of the study
• Subjects not willing and/or not able to comply with scheduled visits and with the requirements of the study protocol, including trial products consumption and food restriction
• Pregnancy (on anamnesis)
• Any direct collaborator of the study leader (Dr. Maurice Beaumont)
• Currently participating or having participated in another clinical trial during the last month prior to the beginning of this study